Vanguard Group’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-3,237,616
| Closed | -$314M | – | 4164 |
|
|
2019
Q3 | $314M | Buy |
3,237,616
+59,859
| +2% | +$5.99M | 0.01% | 1049 |
|
|
2019
Q2 | $325M | Buy |
3,177,757
+166,399
| +6% | +$18M | 0.01% | 1052 |
|
|
2019
Q1 | $343M | Buy |
3,011,358
+94,034
| +3% | +$6.91M | 0.01% | 998 |
|
|
2018
Q4 | $114M | Buy |
2,917,324
+94,156
| +3% | +$4.08M | 0.01% | 1602 |
|
|
2018
Q3 | $154M | Buy |
2,823,168
+67,846
| +2% | +$4.64M | 0.01% | 1564 |
|
|
2018
Q2 | $228M | Buy |
2,755,322
+113,134
| +4% | +$8.73M | 0.01% | 1264 |
|
|
2018
Q1 | $176M | Buy |
2,642,188
+64,909
| +3% | +$3.75M | 0.01% | 1370 |
|
|
2017
Q4 | $133M | Buy |
2,577,279
+111,041
| +5% | +$7.98M | 0.01% | 1562 |
|
|
2017
Q3 | $220M | Buy |
2,466,238
+541,775
| +28% | +$41.1M | 0.01% | 1210 |
|
|
2017
Q2 | $115M | Buy |
1,924,463
+96,803
| +5% | +$5.41M | 0.01% | 1594 |
|
|
2017
Q1 | $97.5M | Buy |
1,827,660
+90,686
| +5% | +$5.38M | 0.01% | 1660 |
|
|
2016
Q4 | $86.7M | Buy |
1,736,974
+52,599
| +3% | +$2.82M | ﹤0.01% | 1714 |
|
|
2016
Q3 | $101M | Buy |
1,684,375
+171,775
| +11% | +$9.9M | 0.01% | 1549 |
|
|
2016
Q2 | $77.3M | Buy |
1,512,600
+338,720
| +29% | +$14.5M | ﹤0.01% | 1682 |
|
|
2016
Q1 | $34.6M | Buy |
1,173,880
+79,142
| +7% | +$2.5M | ﹤0.01% | 2044 |
|
|
2015
Q4 | $49.6M | Buy |
1,094,738
+319,167
| +41% | +$16.7M | ﹤0.01% | 1887 |
|
|
2015
Q3 | $32.4M | Buy |
775,571
+315,256
| +68% | +$16.5M | ﹤0.01% | 2066 |
|
|
2015
Q2 | $27.7M | Buy |
460,315
+35,928
| +8% | +$2.38M | ﹤0.01% | 2207 |
|
|
2015
Q1 | $32.9M | Buy |
+424,387
| New | +$24.4M | ﹤0.01% | 2120 |
|
Vanguard Group's ONCE Position: Q4 2019 in Review
Vanguard Group sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 3,237,616 shares — an estimated $314M sold.
Vanguard Group first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $343M in Q1 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Vanguard Group reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Vanguard Group sold 3,237,616 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $314M.
- Vanguard Group first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
- Vanguard Group's Spark Therapeutics, Inc. Common Stock position peaked at $343M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Vanguard Group's 13F filing for Q4 2019, filed 14 Feb 2020.